# Iron Mountain (IRM) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-10  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/IRM/financials · /stocks/IRM/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/IRM/memo ($2.00, Bearer token).

## Recent Catalysts

# Step 15 — Scenario, Stress, and Base-Rate Analysis

**Company:** Iron Mountain Incorporated (IRM)
**Date:** 2026-04-17
**Sector Track:** REIT
**Assessment:** Mixed — The probability-weighted expected value of ~$120/share is close to the current price of $117.73, suggesting the stock is approximately fairly valued. The distribution is positively skewed (bull case $155 > bear case $75 distance from current), but the leverage profile means the bear case carries outsized risk of permanent capital loss if it materializes.

---

## Key Findings

1. **Four scenarios produce a range of $50-$155/share**: Bull ($155), Base ($118), Bear ($80), and Severe Downside ($50). The probability-weighted expected value is ~$120 — essentially at the current price.

2. **The bull case requires DC re-rating** — if the market begins valuing IRM's DC segment at pure-play multiples, the stock rerate 30%+ to the $150+ range. This is plausible if DC revenue crosses $1.5B and margins sustain 52%+.

3. **The bear case is driven by leverage** — a recession or rate shock would compress AFFO, spike leverage, and potentially force a dividend cut. At 18x the resulting lower AFFO, the stock could trade to $75-80.

4. **The severe downside case ($50) reflects the Gotham thesis** — if AFFO is structurally overstated and true leverage is 8-9x, the stock deserves a deep discount. This is a low-probability but non-trivial scenario.

5. **Base-rate analysis**: IRM's 12% revenue growth is Historically Aggressive for a REIT but Moderately Aggressive for a specialty/technology REIT with a growth portfolio. AFFO growth of 13% is in the top decile of REIT historical outcomes.

---

## Scenario Summary

| Scenario | Probability | FY2029E AFFO/Share | Target Multiple | Fair Value | Weighted Value |
|----------|-----------|-------------------|----------------|-----------|---------------|
| **Bull** | 25% | $9.50 (Hard) | 25x P/AFFO | $155 | $38.75 |
| **Base** | 40% | $8.50 (Hard) | 22x P/AFFO | $118 | $47.20 |
| **Bear** | 25% | $6.00 (Hard) | 18x P/AFFO | $80 | $20.00 |
| **Severe Downside** | 10% | $4.50 (Hard) | 15x P/AFFO | $50 | $5.00 |
| **Probability-Weighted** | 100% | — | — | **$111** | **$111** |

*Note: Probability-weighted value of $111 is ~5% below current price, suggesting modest downside risk at current levels. However, the dividend yield of 2.9% brings total expected return closer to fair.*

### Bull Case Assumptions ($155)
- DC revenue reaches $2.5B by FY2029 (above base $2.0B) — AI demand accelerates
- RIM sustains 6% organic growth (pricing + digital upsell)
- ALM reaches $1.5B as ITAD becomes a major enterprise category
- EBITDA margin reaches 42% (DC at 55%)
- Market re-rates to 25x AFFO (DC peer multiples)
- Leverage declines to 3.8x

### Base Case Assumptions ($118)
- As per Step 13 forecast
- DC revenue reaches $2.0B by FY2029
- EBITDA margin reaches 40%
- Leverage declines to 4.2x
- Multiple stable at 22x

### Bear Case Assumptions ($80)
- DC revenue grows to only $1.3B by FY2029 (demand slows, competition intensifies)
- RIM organic growth decelerates to 3% (pricing pushback)
- ALM flat at $700M (memory pricing collapse, enterprise delays)
- EBITDA margin flat at 37% (DC underperforms)
- Interest rates rise 100 bps, adding $165M annual cost
- Multiple compresses to 18x on leverage concerns

### Severe Downside ($50) — The Gotham Thesis
- AFFO is structurally overstated by 20-30%
- True leverage is 8-9x (Gotham methodology)
- Dividend cut required as AFFO cannot cover distributions
- Equity issuance to deleverage (10-15% dilution)
- Multiple compresses to 15x on trust deficit
- This scenario would require either: a restatement, sustained EBITDA decline, or inability to refinance maturing debt

### Stress Test — Key Variables

| Variable | Base | Stressed | AFFO/Share Impact | Fair Value Impact |
|----------|------|---------|------------------|-------------------|
| Interest rates +100 bps | 5.0% | 6.0% | -$0.55 | -$12 |
| DC revenue -20% | $1,050M (2026) | $840M | -$0.30 | -$7 |
| RIM organic growth → 2% | 5% | 2% | -$0.20 | -$5 |
| ALM memory crash (-50%) | ~$400M* | ~$250M | -$0.25 | -$6 |
| EBITDA margin -200 bps | 37.7% | 35.7% | -$0.50 | -$11 |
| Combined stress | — | — | -$1.80 | -$41 |

*ALM revenue attributable to memory pricing. Combined stress produces a fair value of ~$77, close to the bear case.

### Base-Rate Analysis

| Metric | IRM FY2025 | REIT Median (5Y) | Top Quartile | Alignment |
|--------|-----------|------------------|-------------|-----------|
| Revenue Growth | +12.2% | +5% | +10% | **Top Decile** |
| AFFO Growth | +15% | +5% | +10% | **Top Decile** |
| EBITDA Margin | 37.3% | 45% | 55% | Below Median (mix effect) |
| Net Leverage | 4.9x | 5.5x | 4.0x | Slightly Better Than Median |
| Dividend Growth | +18% | +3% | +8% | **Top Decile** |
| P/AFFO | 22.8x | 18x | 25x | Above Median |

**Assessment:** IRM is operating in the top decile on growth metrics but paying a top-quartile valuation. The growth rates are **Moderately Aggressive** relative to REIT base rates — achievable for 2-3 years but difficult to sustain for 5+. The forecast assumes growth moderates from 12% to 10% by FY2029, which is more realistic.

### Kahneman Bias Checklist

| Bias | Risk | Mitigation |
|------|------|-----------|
| **Anchoring** | Anchored on $5.17 AFFO, which may be overstated | Used "Hard AFFO" ($4.84) as conservative anchor |
| **Saliency** | DC transformation narrative is compelling and easy to overweight | Kept base case conservative (22x, not 25x multiple) |
| **Planning Fallacy** | Forecast assumes smooth growth; reality is lumpier | Stress tests show $77 fair value under combined stress |
| **Groupthink** | Consensus is "Strong Buy" with $120 target — may be too comfortable | Gotham short thesis provides independent counterweight |
| **Competitor Neglect** | Focused on IRM; underweighting Blackstone/QTS (3 GW), CoreWeave | Acknowledged DC scale disadvantage in Step 10 |
| **Sunk Cost / Halo Effect** | Management has executed well → temptation to assume continued success | Insider selling and Gotham critique provide reality checks |

---

## Assumption Register Updates

| ID | Step | Assumption | Type | Value | Unit | Basis | Sensitivity | Source Tags |
|----|------|-----------|------|-------|------|-------|-------------|-------------|
| A40 | 15 | Bull scenario probability: 25% | Judgment | 25% | probability | DC re-rating plausible if revenue exceeds $1.5B | Medium |
| A41 | 15 | Severe downside probability: 10% | Judgment | 10% | probability | Gotham thesis partially valid but full scenario unlikely | Medium |
| A42 | 15 | Probability-weighted fair value: ~$111 | Calculated | $111 | per share | Weighted average of 4 scenarios | High — core output |

---

## Source Index

| Source Tag | Document or URL | Section / Page | Date | Notes |
|------------|----------------|---------------|------|-------|
| [S1] | StockAnalysis.com summary | `other/stockanalysis_summary.md` | 2026-04-17 | Historical data for base rates |
| [S10] | Competitive Landscape | `industry/competitive_landscape.md` | 2026-04-17 | Peer multiples |
| [S14] | Adversarial Research Sweep | `other/adversarial_research.md` | 2026-04-17 | Gotham City thesis |

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/IRM/memo

## Navigation

- Overview: /stocks/IRM
- Financials: /stocks/IRM/financials
- Thesis (this page): /stocks/IRM/thesis
- Investment Memo: /stocks/IRM/memo
- Coverage universe: /stocks